Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in patients (pts) with recurrent glioblastoma (rGBM) treated with bevacizumab (BEV) and sorafenib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback